Local Government Mandate Statement Kentucky Legislative Research Commission 2024 Regular Session

Part I: Measure Information

Bill Request #: 1792						
Bill #: HB 534 GA						
Document ID #: 7823						
Bill Title: AN ACT relating to addiction treatment.						
Sponsor: Representative Robert Duvall						
Unit of Government: X City X County X Urban-County Unified Local						
<u>X</u> Charter County <u>X</u> Consolidated Local <u>X</u> Government						
Office(s) Impacted: All offices that offer health insurance for their employees.						
Requirement: X Mandatory Optional						
Effect on Powers & Duties: Modifies ExistingX_ Adds New Eliminates Existing						

Part II: Bill Provisions and the Estimated Fiscal Impact Relating to Local Government

Section 2 of HB 534 GA amends KRS 304.17A-611 to prohibit health benefit plans from conducting a prospective or concurrent review for a prescription drug that contains an opioid antagonist.

HB 534 GA may have an indeterminable and likely negligible impact on local governments. There are already drugs with similar prohibitions that currently exist— Methadone, Buprenorphine, and Naltrexone. By preventing health benefit plans from conducting prospective or concurrent reviews for prescriptions drug that contains an opioid antagonist, there may be a smaller administrative burden on health benefit plans cutting wait times for patients with prescriptions for those drugs; however, that is unknown at this time. LRC staff also reached out to the Kentucky Association of Counties (KACo). KACo believes this bill would have a negative fiscal impact on counties; however, KACo believes the impact would be minimal.

LRC staff also reached out to the Kentucky League of Cities (KLC). KLC does not believe HB 534 would have a fiscal impact. .

Data Source(s): <u>LRC Staff</u>

Preparer:	Bart Liguori (MS)	Reviewer:	KHC	Date:	3/11/24
------------------	-------------------	------------------	-----	-------	---------